Download the complete journal: here

Tailoring Hormone Replacement Therapy (HRT) for Osteoprotection

Summary

• HRT alone is inadequate for osteoporosis treatment without concomitant calcium intake.
  
  
• The non-oral form of oestrogen replacement therapy (ERT) is more physiological than the oral form, with fewer unpleasant side effects.
  
  
• Tibolone is preferable in women with benign breast disease, endometriosis, pre-existing fibroids or those with increased risk of breast cancer.
  
  
• Patients on HRT must be reviewed annually along with regular mammographic assessment at least every 2 years.
  
  
• A minimum of 5-years' therapy is recommended to derive the optimum benefit of HRT in osteoporotic women.

Editor's Comment

Selection of the right patient to initiate a particular form of HRT and/or it's modified analogues is of primary importance so as to achieve success in tackling the menace of osteoporosis in postmenopausal women. According to the author, an individualistic approach is required for tailoring HRT in osteoporotic patients.

[ Home ] [ Current Issue ] [ ]